On January 28, Novartis announced that inclisiran sodium injection (brand name: Leqvio) had been approved by the NMPA for a new indication. As an adjunct to diet, it may be used as monotherapy in adults with primary hypercholesterolemia (non-familial) or mixed dyslipidemia to reduce low-density lipoprotein cholesterol (LDL-C).
This means that, in addition to its previously approved indications for use with statins or with statins plus other lipid-lowering therapies, inclisiran now covers more patients with dyslipidemia who need treatment.
Inclisiran is the world’s first and currently only ultra-long-acting small interfering RNA drug for lowering LDL-C. It inhibits synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9), reduces intracellular and extracellular PCSK9 levels, and thereby markedly lowers LDL-C concentrations.
Based on the unique advantages of oligonucleotide medicines, the drug requires administration only twice a year and has enormous potential as a chronic-disease therapy. Novartis acquired this blockbuster in a USD 9.7 billion transaction in 2019.
Overseas, inclisiran was approved by the EMA in 2020 and by the FDA in 2021 for adult hypercholesterolemia and mixed dyslipidemia.
In July 2023, the FDA approved a label update allowing inclisiran as an adjunct to diet and statin therapy for primary prevention in patients with elevated LDL-C and additional cardiovascular risk factors such as hypertension or diabetes. In July 2025, the FDA again updated the label to allow inclisiran as first-line monotherapy used with diet and exercise, without a mandatory statin requirement.
In China, inclisiran was first approved in August 2023 as an adjunct to diet for adults with primary hypercholesterolemia, including heterozygous familial and non-familial disease, or mixed dyslipidemia. In the 2025 national reimbursement negotiations, it was successfully added to the National Reimbursement Drug List.
To date, the drug has been approved in nearly 100 countries, including the United States, the European Union, and China.
At the 2025 European Society of Cardiology (ESC) Congress, Novartis announced results from the VICTORION-Mono China study, the first clinical trial in a Chinese population to evaluate inclisiran as monotherapy.
VICTORION-Mono China is a randomized, double-blind, placebo-controlled Phase III clinical trial (NCT05888103/CTR20231739) evaluating the efficacy and safety of inclisiran monotherapy in Chinese adults with elevated LDL-C who had low or moderate risk of atherosclerotic cardiovascular disease (ASCVD) and were not receiving any lipid-lowering treatment.
A total of 207 patients were randomized to inclisiran (n=103) or placebo (n=104). The mean age was 47.9 years, 58.5% were female, and the mean baseline LDL-C was 149.9 mg/dL. Among them, 167 patients (80.7%) were at low ASCVD risk and 37 (17.9%) were at moderate risk.
Results showed that inclisiran met the primary endpoint. From baseline to Day 150, the placebo-adjusted mean percentage change in LDL-C was -47.50% (95% CI: -52.35, -42.65; p<0.0001), and the placebo-adjusted absolute change in LDL-C at Day 150 was -69.73 mg/dL (95% CI: -76.60, -62.86; p<0.0001).
For secondary endpoints, inclisiran also reduced PCSK9 (-77.83%), total cholesterol (-31.49%), non-HDL-C (-40.57%), and ApoB (-36.84%) after Day 150 (all p<0.0001). At Day 330, the mean percentage change in LDL-C in the inclisiran group was -45.45% (95% CI: -48.57, -42.34).
In terms of safety, adverse event rates were similar between inclisiran and placebo (70.9% vs 67.3%). Treatment-related adverse events were slightly higher in the inclisiran group (13.6% vs 3.8%) but were not severe.
The China Lipid Management Guidelines (2023) note that more than 400 million people in China have dyslipidemia and that onset is occurring at younger ages. Thanks to the long-acting advantage of only two injections per year, global sales of inclisiran rose from USD 12 million in 2021 to USD 754 million in 2024, making it Novartis’ second-largest cardiovascular product. With progressive approval of new indications, sales continue to climb rapidly.
Competition around the PCSK9 target remains intense. Insight database shows 55 PCSK9-targeted programs worldwide in clinical development. Approved drugs are mainly monoclonal antibodies, including Amgen’s evolocumab and Regeneron/Sanofi’s alirocumab, as well as domestic products from Hengrui, Innovent, Akeso, and Junshi. Among investigational products, oral drugs, siRNA agents, and ASOs predominate, such as Merck’s oral synthetic peptide enlicitide and AstraZeneca’s oral small molecule laroprovstat, both already in Phase III development. Domestic companies including CSPC Group and Qilu/Ribo are also developing PCSK9 siRNA drugs.
It can be expected that new medicines led by inclisiran will soon bring better treatment options and improved quality of life to people with dyslipidemia.